Search for: "Sanofi-Aventis US Inc"
Results 61 - 80
of 160
Sorted by Relevance
|
Sort by Date
2 Dec 2009, 4:31 am
Because other countries just decide to pay less – Pfizer’s patent battle against UniLab (Patent Baristas) Moxifloxacin – Venezuela annuls two of Bayer’s patents relating to Moxifloxacin (IP tango) (IP tango) Plavix (Clopidogrel) – India: Indian company, Cadila, bears the brunt of section 3(d) (Spicy IP) Sanctura (Trospium) – US: Allergan files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs) Taxotere (Docetaxel)… [read post]
9 Nov 2020, 3:00 am
LLC Sanofi US Services Inc. [read post]
9 Nov 2020, 3:00 am
LLC Sanofi US Services Inc. [read post]
9 Nov 2020, 3:00 am
LLC Sanofi US Services Inc. [read post]
15 Apr 2021, 10:51 am
Sanofi-Aventis U.S. [read post]
23 Sep 2021, 2:10 am
Inequitable conduct includes, for example, intentionally failing to disclose information to the USPTO that is material to the patentability of an application (see also Sanofi-Aventis v Hospira, IPKat). [read post]
10 Aug 2011, 4:30 am
(Patent Docs) Prezista (Darunavir) – US: Patent infringement complaint filed following a Paragraph IV certification: Tibotec Inc. et al. v. [read post]
3 Nov 2010, 7:00 am
("Amphastar") sued FDA over FDA's decision to detain imported raw material used to make a generic form of Lovenox® (enoxaparin sodium), the blockbuster, heparin-based blood thinner sold by Sanofi-Aventis SA. [read post]
8 Jul 2011, 11:04 am
IMS Health Inc., ___ U.S. ___, 2011 WL 2472796, at *8 (U.S. [read post]
14 Dec 2010, 7:06 pm
Karst – When we last left you in the battle over FDA’s approval of a generic version of sanofi-aventis U.S. [read post]
1 Apr 2010, 3:04 am
USPTO and Myriad Genetics (Docket Report) (Peter Zura's 271 Patent Blog) (Inventive Step) (Patently-O) (Holman's Biotech IP Blog) (Patent Docs) (Ladas & Parry) (Tech Transfer Blog) (ipwars.com) (Ars Technica) (BlawgIT) (IP Watch) (The Prior Art) US: Study suggests USPTO erred in broad claims of Myriad BRCA1 patent (Tech Transfer Blog) (Patent Docs) US: CAFC confirms written description requirement in Ariad v Lilly (IP Law Blog) (IP Osgoode) (IP Spotlight) (Ars… [read post]
10 Jun 2010, 3:58 am
Kappos (Patent Docs) Products Allegra (Fexofenadine) - US: Patent infringement complaint following a Paragraph IV certification: Sanofi-Aventis U.S. [read post]
8 Feb 2011, 10:51 pm
(FDA Law Blog) US: Another academic with solutions to problems that don’t exist (Patent Docs) US: Syngenta files for declaratory judgment of invalidity and non-infringement of Bayer’s patents based on its development of GM crops containing HPPD gene (Patent Docs) US: District Court New Jersey: Loss of market share to infringing competitor during six year reexamination warrants denial of stay: Wyeth et al v Abbott (Docket Report) US: District Court New… [read post]
5 May 2010, 4:46 am
(Patent Docs) Plavix (Clopidogrel) – Netherlands: District Court of The Hague finds Sanofi-Aventis’ patent invalid for lack of inventive step in proceedings brought by RatioPharm (EPLAW) Rapamune (Sirolimus) – US: Patent infringement complaint following Paragraph IV certification: Pfizer Inc. et al. v. [read post]
7 Feb 2012, 2:25 pm
’s (“Sandoz’s”) ANDA No. 077857 for a generic version of Sanofi-aventis U.S. [read post]
25 Aug 2017, 7:02 am
” The allegations against Mylan were brought to court by pharmaceutical manufacturer Sanofi-Aventis US LLC under a provision of the False Claims Act that permits private qui tam whistleblowers to sue alleged wrongdoers on behalf of the federal government. [read post]
25 Aug 2017, 7:02 am
” The allegations against Mylan were brought to court by pharmaceutical manufacturer Sanofi-Aventis US LLC under a provision of the False Claims Act that permits private qui tam whistleblowers to sue alleged wrongdoers on behalf of the federal government. [read post]
15 May 2011, 2:54 pm
Karst – Last week, the Federal Trade Commission (“FTC”) announced that the Commission’s Bureau of Competition (“Bureau”) sent letters (here, here, and here) to Sanofi-Aventis U.S. [read post]
3 Jun 2010, 5:35 am
– In re Ciprofloxacin Antitrust Litigation (PatLit) Circumvent PCV and Porcilis PCV vaccines – US: Wyeth files patent infringement suit against Intervet based on their manufacture of PCV vaccines (Patent Docs) Copegus (Ribavirin) – US: Ascio seeks declaratory judgment of unenforceability, invalidity and non-infringement of Three Rivers’ patent based on ANDA filing (Patent Docs) Entocort (Budesonide) – US: AstraZeneca settles Entocort patent… [read post]
25 Jan 2009, 2:36 pm
The last big pharmaceutical industry acquisition came in August 2004, when Paris-based Sanofi-Synthelabo acquired Aventis SA of Strasburg, France, for $64.4 billion to create Sanofi Aventis SA, France's largest drugmaker. [read post]
